Despite encouraging clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial resistance from pharmacy benefit managers. The insurers are https://jasonmppj820533.link4blogs.com/62871355/the-medication-faces-is-meeting-managed-care-organization-hurdles-a-look-of-reimbursement-battles